New York, November 18, 2015 -- The ongoing US government and market scrutiny of Valeant Pharmaceuticals International Inc.'s (Valeant) and other drug companies' pricing practices will curtail gains collateralized loan obligations (CLOs) have recently made on merger and acquisition (M&A) activity in the generic and specialty pharmaceutical sector. However, according to a new report from Moody's, "Side Effects of Pharma Price Scrutiny Will Stem CLO Gains from M&A Activity," these negative sector developments will have only limited credit implications for CLOs.

Vollständigen Artikel bei Moodys lesen